Drug Profile
SLC 022
Alternative Names: Glial cell modulator - Solace Pharmaceuticals; SLC022Latest Information Update: 29 Jun 2015
Price :
$50
*
At a glance
- Originator Solace Pharmaceuticals
- Class
- Mechanism of Action Glial cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postherpetic neuralgia
Most Recent Events
- 12 Jan 2009 Phase-II clinical trials in Postherpetic neuralgia in USA and Germany (PO)